#Taiwan #San Diego #biotechnology #BIO 2026

Taiwan's Prominence at BIO International Convention 2026

From June 22 to 25, 2026, Taiwan will showcase its burgeoning biotechnology sector at the BIO International Convention held in San Diego. With a focus on deepening global partnerships and highlighting its innovative landscape, Taiwan’s delegation is expected to present cutting-edge advancements from 33 companies, showcasing over 40 groundbreaking technologies.

Supported by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) and the Ministry of Economic Affairs, the events at the Taiwanese Pavilion (Booth #2621) aim to reinforce Taiwan's status as one of Asia’s premier biotechnology hubs. The theme for this year is "Taiwan, Your Best Partner in Asia," which aligns with the strategic goals established at the previous BIO 2025 event. The Taiwanese delegation is geared toward leveraging this platform to foster collaborations in drug development, biomanufacturing, digital health, and precision medicine.

Key Engagement Opportunities

Taiwan's participation includes several key events designed to engage and connect with global stakeholders. Among them are:

• - BIO Session on Chronic Disease Management (June 22, 1:45 – 2:45 PM, Room 29AB): Experts from Taiwan, the U.S., Singapore, Japan, and South Korea will convene to discuss insights into chronic disease management and the economic implications of Health Technology Assessment (HTA).
• - Start-Up Stadium Highlighting Vacino Biotech (June 22, 4:50 – 5:00 PM, Room 5B): A spotlight on emerging innovations in biotechnology.
• - Global Innovation Hub (June 23, 2:30 – 2:45 PM, Room 5A): A forum to delve into Taiwan's thriving biotech ecosystem and its dynamic startup culture.
• - Taiwan Happy Hour Networking Reception (June 23, 4:00 – 5:00 PM, Taiwan Pavilion): A networking opportunity for over 200 biotech leaders and investors.

As Taiwan's biotechnology industry continues to thrive, it is estimated to have generated a staggering NT$775.4 billion (around US$25 billion) in revenue in 2024, with a combined market value exceeding NT$1.47 trillion. The growing number of biotech companies listed on both stock exchanges and over-the-counter markets showcases Taiwan's potential and strategic importance in the global biotechnology sector.

Michael Huang, Director of BPIPO, commented, "BIO 2026 offers a crucial opportunity for Taiwan's biotech industry to exhibit its robust manufacturing capabilities while forging international partnerships." He further mentioned that this event is vital for Taiwan to explore new avenues for collaboration and licensing agreements in the healthcare innovation arena.

Conclusion

The BIO International Convention in San Diego represents a significant milestone for Taiwan's biotech presence on a global stage. By highlighting its advanced capabilities and innovative developments, Taiwan is not only demonstrating its key role in the biotechnology field but is also paving the way for future collaborations that can enhance the healthcare and life sciences landscape worldwide.